- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06365528
Tunneled Peripherally Inserted Central Catheter (PICC) in Adult Patients and Associated Outcomes
Tunneled Versus Non-Tunneled Peripherally Inserted Central Catheter and Their Effects on Reducing Combined or Isolated Outcomes (Obstruction, Infection, Thrombosis, and Dislodgement): Multicenter Randomized Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The data published this year from a multicenter study in Brazil presenting the patterns of use and clinical outcomes of PICC indicated that centers with vascular access teams, adoption of best practices, and current technologies result in low rates of complications, such as primary bloodstream infections related to the catheter, deep vein thrombosis, and reversible occlusion. Despite these more recent data showing that complications related to PICC can be mitigated by the use of technology, vascular access teams, adoption of best practices, and infection control measures, there is still room to incorporate new techniques in PICC insertion with the aim of further reducing avoidable complications. For example, recent studies with robust methodology have demonstrated the benefit of the tunneling technique compared to the conventional insertion technique. A randomized clinical trial showed that the dwell time of the device inserted using the tunneling technique was longer compared to the conventional technique without tunneling in adult patients, along with a lower incidence of thrombosis and infection. At the Hospital de Clínicas de Porto Alegre, recently, nurses from the PICC Team were trained in the tunneling technique at a reference center in Brazil. The initial results of tunneling in adult, pediatric, and neonatal patients are encouraging.
The observed results of implementing the technique indicate that there is potential to reduce avoidable complications and prompt us to propose a multicenter randomized controlled trial involving two additional institutions with similar profiles regarding the composition of Vascular Access Teams, adoption of best practices related to catheter care, and active ongoing education. To our knowledge, robust studies of this nature are not currently being conducted in Brazil.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Eneida R Rabelo da Silva, ScD
- Phone Number: 5551998068616
- Email: eneidarabelo@gmail.com
Study Locations
-
-
-
Porto Alegre, Brazil
- Hospital de Clínicas de Porto Alegre
-
Contact:
- Eneida R Rabelo da Silva, ScD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- adult patients (>= 18 years old) admitted to medical clinics, surgical clinics, or ICU, who have an indication for PICC insertion;
Exclusion Criteria:
- patients with Chronic Kidney Disease, whether dialytic or not;
- patients in critical or unstable condition characterized by the need for intubation, respiratory rate <8 or >35 breaths per minute, oxygen saturation <90%, heart rate <40 or >140 beats per minute, systolic blood pressure <90mmHg, decreased Glasgow Coma Scale >2 points, or prolonged (>5 minutes) or repeated seizures;
- patients with cognitive deficits that impair their understanding of the study and do not have a responsible party to assist in this stage.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tunneled PICC
The intervention group will consist of adult patients who will have PICCs inserted using the catheter tunneling technique.
The technique involves the catheter being exteriorized through the skin at a site different from the blood vessel puncture site, thus traversing a subcutaneous tunnel.
|
The Subcutaneous tunnelling group will undergo PICC placement under ultrasonography.
Procedures will be implemented under hand hygiene, maximal sterile barrier, and chlorhexidine.
The targeted arm will be sterilized with a mixture of chlorhexidine and isopropyl alcohol, and a sterile drape will be placed to cover the entire procedure feld from head to toe and place with additional subcutaneous tunnelling.
After vein puncture with the access needle, a Nitinol guidewire will be placed as usual.
We will make a tunnel distal to the initial venepuncture site using an additional 14-gauge needle.
After resolution of the loop over the venepuncture site, a peel-away sheath will be placed over the wire.
The catheter will be trimmed to the distance between the venepuncture site and cavoatrial junction plus the subcutaneous tunnel before being inserted in the usual manner.
|
Active Comparator: Non-tunneled PICC
The control group will consist of adults patients who will have PICCs inserted using the conventional technique
|
The Non-tunnelling group will have PICC placement with the traditional method under ultrasonography.
Procedures will be implemented under hand hygiene, maximal sterile barrier, and chlorhexidine.
The targeted arm will be sterilized with a mixture of chlorhexidine and isopropyl alcohol, and a sterile drape will be placed to cover the entire procedure feld from head to toe.
After vein puncture with the access needle, a Nitinol guidewire will be placed.
After, a peel-away sheath will be placed over the wire.
The catheter will be trimmed to the distance between the venepuncture site and cavoatrial junction.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
End of therapy or catheter removal free from complications
Time Frame: Up to 30 days, end of therapy or withdrawal due to any complication
|
Time in days
|
Up to 30 days, end of therapy or withdrawal due to any complication
|
Collaborators and Investigators
Investigators
- Principal Investigator: Eneida R Rabelo da Silva, ScD, Hospital de Clínicas de Porto Alegre
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-0232
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Deep Vein Thrombosis
-
University of OklahomaPfizerCompleted
-
University Medical Center GroningenCompletedSuspected Upper Extremity Deep Vein ThrombosisAustria, Netherlands, Italy, Belgium, Switzerland, Germany, United States
-
National Taiwan University HospitalUnknownUpper Extremity Deep Vein Thrombosis, SecondaryTaiwan
-
University of Missouri-ColumbiaTerminatedDEEP VEIN THROMBOSISUnited States
-
Vetex Medical Ltd.CompletedDeep Vein Thrombosis LegIreland, Germany, Bulgaria, United Kingdom
-
MinaPharm PharmaceuticalsRecruitingProphylaxis of Deep Vein ThrombosisEgypt
-
UPECLIN HC FM Botucatu UnespCompletedProphylaxis of Deep Vein ThrombosisBrazil
-
McMaster UniversityCanadian Institutes of Health Research (CIHR)CompletedSuspected Deep Vein ThrombosisCanada
-
Diakron PharmaceuticalsCompleted
-
BayerRecruitingThrombolysis | Symptomatic Proximal Deep Vein ThrombosisBelgium, France, Italy, Netherlands, Canada, Germany
Clinical Trials on Subcutaneous tunnelling
-
Beijing Friendship HospitalUnknown
-
Regado Biosciences, Inc.CompletedHealthy VolunteerUnited States
-
Astellas Pharma Europe B.V.CompletedHealthy Subjects | Pharmacokinetics of ASP6294United Kingdom
-
The University of The West IndiesNot yet recruitingOverweight or Obese Women, Elective Lower Segment Cesarean Section
-
Eli Lilly and CompanyCompleted
-
Ain Shams UniversityCompleted
-
AlRefaey KandeelCompleted
-
University Hospital, LimogesTerminated
-
Boston Scientific CorporationCompletedHeart Failure | Long QT Syndrome | Wide QRS Complexes | Cardiac ResynchronisationUnited Kingdom